Axxam SpA is a member of the PHAGO Consortium
Axxam announce its participation to the PHAGO project, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD). Axxam will contribute its expertise for the development of high-throughput screening systems suitable for the discovery of modulators of the TREM2/CD33 pathway. For more info please open the Press Release from the PHAGO Consortium. More info: http://www.axxam.com/sites/default/files/uploads/news/attachments/205/pressreleasephago20170111engl.pdf. Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand
Zambon and Seqirus announced that they have entered into a long term partnership covering Zambon’s Parkinson’s Disease product, in Australia and New Zealand. Zambon will be responsible for product supply and Seqirus will undertake registration and commercialisation of the product. Roberto Tascione, CEO of Zambon said “Expanding the reach of Zambon’s products by entering new growth markets is an important part of our strategy. Seqirus is an attractive partner being a large local pharmaceutical company in Australia with a prominent track record in neurology. Australia and New Zealand are markets with resilient economies, substantial disease prevalence and established Parkinson’s Disease markets”. More info: http://www.newron.com/en Newron Pharmaceuticals S.p.A., preliminary results of the use of Evenamide in patients with schizophrenia
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, announced preliminary results of a Phase IIa study with its unique sodium channel blocker, Evenamide (NW-3509), in patients with schizophrenia. The new chemical entity is orally available and specifically targets voltage-gated sodium channels by a unique mechanism of action. The results of the study indicate that patients treated with Evenamide showed improvement on the symptoms of schizophrenia assessed by (the Positive and Negative Syndrome Scale) PANSS, as well as functioning assessed by the Strauss-Carpenter Level of Functioning scale, compared to their standard antipsychotic. In addition, a global assessment of change from baseline in the patient’s overall condition (Clinical Global Impression of Change), performed by a clinician, showed a greater proportion of Evenamide-treated patients rated as improved (54%), compared to placebo (36%). More info: http://www.newron.com/en Kedrion Biopharma strengthens its presence in Russia
By signing a Memorandum of Understanding with leading Russian pharmaceutical holding companies National Immunobiological Company (Nacimbio) and Pharmstandard, Kedrion Biopharma further strengthens its presence in Russia. Kedrion Biopharma and Nacimbio, part of the State-owned Rostec group, whose mission is to reduce Russian dependence from the importation of life-saving human plasma derived therapies, are joined by new partner Pharmastandard, a leading Russian company specializing in the development and manufacturing of pharmaceutical products. This Italian-Russian partnership aims to implement a joint program that will lead to manufacturing plasma-derived products in the Russian Federation; specifically, it aims to finalize the construction of production plant in Kirov, Russia. The parties are committed to establishing - by January 2017 - a joint venture, shares in which will be owned by Nacimbio (37.5%), Pharmastandard (37.5%) and Kedrion (25%). The joint venture will determine the industrial plan for, and complete the construction of, the Kirov-based plant. In the new organization, Kedrion will uphold its role as principal technological partner, whereas Pharmastandard steps in to provide financial backing. More info: https://www.kedrion.com/kedrion-biopharma-strengthens-its-presence-russia The European Medicines Agency has validated the submission of Conditional Marketing Authorisation for NGR-hTNF
MolMed S.p.A. announces that the European Medicines Agency (EMA) has validated the submission of the Conditional Marketing Authorisation (CMA) application for NGR-hTNF as treatment of adult patients with malignant pleural mesothelioma progressing within six months after the first-line pemetrexed-based therapy. NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to tumour blood vessels and concentration of immune system cells into the tumour mass. More info: http://www.molmed.com/sites/default/files/uploads/press-releases/3027/3027_1482413497.pdf Bio-on announces new multi-license maxi agreement for revolutionary phas bioplastic
Bio-on announces it has signed a new multi-license contract worth 55 million Euro with a major multinational company and leader in its sector. The goal of Bio-on's new client is, within the next 3 years, to replace conventional plastic with biodegradable biopolymers made from agro-industrial waste using Bio-on's revolutionary PHAs bioplastic. Thus transforming waste into raw material, using a new plastic with a positive impact on people and the planet. The first license comes into effect on signing the agreement, while a second will be activated in the first half of 2017, concluding the preparatory activities for the launch of the industrial project. All licenses and relative revenues, for a total of 55 million Euro, will be developed continuously over the next 24-36 months. More info: http://www.bio-on.it/news.php?lin=inglese
Lo scopo del documento di posizione è fornire supporto su una specifica tematica. Esso descrive una posizione su un problema e il razionale per quella posizione.